This is an archive page. The links are no longer being updated.

Date: Tuesday, October 8, 1996
FOR IMMEDIATE RELEASE
Contact: NIH, NCI Press Office (301) 496-6641

NCI's Largest Cancer Screening Trial Seeks Men and Women Ages 55 to 74

Moving into the final recruitment phase, the researchers of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) are seeking 75,000 more men and women ages 55 to 74 to help them determine whether medical tests to detect some of the most common cancers reduce the number of deaths from these diseases. This largest-ever U.S. cancer screening trial will include a total of 148,000 men and women in 10 cities: Denver, Colo.; Washington, D.C.; Honolulu, Hawaii; Detroit, Mich.; Minneapolis, Minn.; St. Louis, Mo.; Brooklyn, N.Y.; Pittsburgh, Pa.; Salt Lake City, Utah; and Marshfield, Wis.

Together, prostate, lung, colorectal, and ovarian cancers account for nearly half of all cancers diagnosed and half of all cancer deaths in the United States. Late in 1995, the age range for PLCO trial participants was expanded from ages 60 to 74 to ages 55 to 74. AAlmost 80 percent of cancers occur in people who are age 55 and older,@ said John Gohagan, Ph.D., chief of NCI's Early Detection Branch and project officer for the study. ABy lowering the age for participation, we are including more people who are already at risk.@ The study got under way in November 1993.

The tests being studied may detect these cancers before symptoms develop, but whether treatments at this stage will reduce the chance of dying from the diseases is unknown. Some cancer screening tests very clearly reduce the number of deaths from the disease, such as Pap tests which reduce deaths from cervical cancer. But many other medical tests are being routinely used to screen healthy people for cancer when there is no definitive evidence that they reduce the number of deaths from the disease.

PLCO trial participants are randomized (selected by chance) to one of two groups: Half the participants undergo the tests being studied (intervention group), and half receive whatever usual health care their doctors provide (control group). Both groups will answer yearly questionnaires about their health.

Whether the participants receive their usual care from their physicians or receive cancer screening tests at the PLCO centers, they are playing an important role,@ said Gohagan. By comparing the numbers of cancers diagnosed, side effects of treating the cancers, and the numbers of cancer deaths in the intervention group with those in the control group, the researchers will be able to determine if the cancer screening tests had an overall benefit. The tests being studied are:

• For prostate cancer, men have a digital rectal exam of the prostate and a blood test for prostate-specific antigen, known as PSA.
  
• For lung cancer, both men and women receive a regular chest x-ray.

• For colorectal cancer, men and women are screened with a lighted instrument called a
• flexible sigmoidoscope that lets health professionals see the
• inside of the rectum and the lower part of the colon.
  

• For ovarian cancer, women have a physical exam of the ovaries, a blood test for the tumor marker known as CA125, and a test called transvaginal ultrasound.
  

The intervention group has these tests done at their initial visit and once every year for the next three years, except for the sigmoidoscopy exam, which is performed only twice -- during the initial visit and during the third year of their participation. Participants in both the intervention and control groups are contacted yearly for at least 10 years from the time they enter the study in order for the researchers to monitor their health.

Men and women interested in participating in the PLCO trial should contact the center nearest them. Locations of the centers can be found by calling NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). Information about the PLCO Trial can also be found on the World Wide Web (Internet) at: www.dcpc.nci.nih.gov/PLCO.

The Cancer Information Service provides a nationwide telephone service for cancer patients and their families, the public, and health care professionals. The toll-free number is 1B800B4BCANCER (1B800B422B6237); services provided in English and Spanish. People with TTY equipment may call 1B800B332B8615.

This document is available through the NCI's CancerNet services on the Web (cancernet.nci.nih.gov) and through Cancer Fax (dial 301-402-5874 from the handset on your fax machine).